FDA approves new drug for rare genetic disease
The Food and Drug Administration has approved a new capsule-based drug to treat Gaucher's disease.
Aug 19, 2014
0
0
The Food and Drug Administration has approved a new capsule-based drug to treat Gaucher's disease.
Aug 19, 2014
0
0
A targeted gene silencing strategy blocks production of the dysfunctional huntingtin (Htt) protein, the cause of Huntington's disease, a fatal, inherited neurodegenerative disorder. The effectiveness of this RNA interference ...
May 21, 2014
0
0
French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.
Dec 30, 2013
0
0
A transformational new treatment for multiple sclerosis (MS) - the result of over three decades of research in Cambridge - was approved today by the EU agency responsible for regulating new drugs.
Sep 18, 2013
0
0
Findings from postmortem studies of the brains of Huntington's Disease (HD) patients suggest that transcriptional dysregulation may be an early step in the pathogenesis of HD before symptoms appear. Other studies report transcriptional ...
Aug 26, 2013
0
0
Osteoarthritis that often develops in people after knee surgery will be a thing of the past if a young researcher at The University of Western Australia is successful.
Aug 12, 2013
0
0
LDL cholesterol is not a useful marker of heart disease risk in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The finding suggests ...
May 16, 2013
0
0
(AP)—French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.
May 2, 2013
0
0
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease. ...
Feb 22, 2013
0
0
(HealthDay)—Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood.
Jan 30, 2013
0
0
Genzyme Corporation (NASDAQ: GENZ) is a fully owned subsidiary of Sanofi-Aventis. Before its acquisition, Genzyme was an American biotechnology company based in Cambridge, Massachusetts. In 2010, Genzyme was the world’s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi-Aventis, Genzyme has a presence in approximately 40 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories, its products are sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenues with more than 25 products in the market. In 2006 and 2007 Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators.
This text uses material from Wikipedia, licensed under CC BY-SA